In January of this year, the FDA noted that it had "received adverse event reports after patients used compounded semaglutide" and that "patients should not use a compounded drug if an approved drug is available to treat a patient." In July, the agency followed up with a notice that it had "received reports of adverse events, some requiring hospitalization, that may be related to overdoses due to dosing errors associated with compounded semaglutide injectable products." And in August, Eli Lilly, the maker of Zepbound and Mounjaro, sent a series of cease-and-desist letters to providers urging them to stop prescribing compounded versions of those drugs
In clinical use, LDN has shown promise in patients with: Importantly, LDN can help calm the immune system, reduce neuroinflammation, and begin to restore balance in the gut microbiomeproviding a crucial foundation for hormonal and metabolic therapies
Eli Lilly's work in weight loss should be a significant tailwind beyond the next decade, considering the company is still innovating, and these medicines won't hit patent cliffs anytime soon
doi: 10.3892/ijmm.2020.4498 281 BartelDP
Sterilized bifidobacteria suppressed fat accumulation and blood glucose level
2025;3(7):luaf104